Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1997-8-4
|
pubmed:abstractText |
1. Ro 32-3555 (3(R)-(cyclopentylmethyl)-2(R)-[(3,4,4-trimethyl-2,5-dioxo-1- imidazolidinyl)methyl]-4-oxo-4-piperidinobutyrohydroxamic acid) is a potent, competitive inhibitor of human collagenases 1, 2 and 3 (Ki values of 3.0, 4.4 and 3.4 nM, respectively). The compound is a selective inhibitor of collagenases over the related human matrix metalloproteinases stromelysin 1, and gelatinases A and B (Ki values of 527, 154 and 59 nM, respectively). 2. Ro 32-3555 inhibited interleukin-1 alpha (IL-1 alpha)-induced cartilage collagen degradation in vitro in bovine nasal cartilage explants (IC50 = 60 nM). 3. Ro 32-3555 was well absorbed in rats when administered orally. Systemic exposure was dose related, with an oral bioavailability of 26% at a dose of 25 mg kg-1. 4. Ro 32-3555 prevented granuloma-induced degradation of bovine nasal cartilage cylinders implanted subcutaneously into rats (ED50 = 10 mg kg-1, twice daily, p.o.). 5. Ro 32-3555 dosed once daily for 14 days at 50 mg kg-1, p.o., inhibited degradation of articular cartilage in a rat monoarthritis model induced by an intra-articular injection of Propionibacterium acnes. 6. Ro 32-3555 is a potential therapy for the treatment of the chronic destruction of articulating cartilage in both rheumatoid and osteoarthritis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0007-1188
|
pubmed:author |
pubmed-author:BishopJJ,
pubmed-author:BottomleyK MKM,
pubmed-author:BradshawDD,
pubmed-author:BrewsterMM,
pubmed-author:BroadhurstM JMJ,
pubmed-author:BrownP APA,
pubmed-author:BuddJ MJM,
pubmed-author:ElliottLL,
pubmed-author:GreenhamA KAK,
pubmed-author:JohnsonW HWH,
pubmed-author:LevinD ADA,
pubmed-author:NixonJ SJS,
pubmed-author:RoseFF,
pubmed-author:SuttonBB,
pubmed-author:WilsonKK
|
pubmed:issnType |
Print
|
pubmed:volume |
121
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
540-6
|
pubmed:dateRevised |
2008-11-20
|
pubmed:meshHeading |
pubmed-meshheading:9179398-Administration, Oral,
pubmed-meshheading:9179398-Animals,
pubmed-meshheading:9179398-Arthritis, Experimental,
pubmed-meshheading:9179398-Cartilage,
pubmed-meshheading:9179398-Cattle,
pubmed-meshheading:9179398-Collagenases,
pubmed-meshheading:9179398-Humans,
pubmed-meshheading:9179398-Imidazoles,
pubmed-meshheading:9179398-Male,
pubmed-meshheading:9179398-Protease Inhibitors,
pubmed-meshheading:9179398-Rats,
pubmed-meshheading:9179398-Rats, Sprague-Dawley
|
pubmed:year |
1997
|
pubmed:articleTitle |
Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo.
|
pubmed:affiliation |
Roche Discovery Welwyn, Welwyn Garden City, Herts.
|
pubmed:publicationType |
Journal Article
|